MYGN at a glance
MYRIAD GENETICS INC (MYGN, SEC CIK 899923) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on July 31, 2026, an 8-K current report on September 16, 2026 and Form 4 insider filings as recently as September 22, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), MYRIAD GENETICS INC (MYGN) reported revenue of $824.5 million (down 1.6% from FY2024) and a net loss of $365.9 million. Diluted EPS was -$3.95.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding MYRIAD GENETICS INC (MYGN) shares worth $290.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Kumar Rashmi on June 8, 2026 of 15,000 shares at $4.46 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $824.5M
- −1.6% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $290.0M · −1 vs prior quarter
- Latest 8-K
- Sep 16, 2026
- Item 5.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $190.7M, down $22.4M YoY, with $11.0M reduction from prior-period collection estimates
- Cost-of-revenue margin 33.4% vs 28.8% YoY, while sales and marketing expense reached 43.6% vs 33.7%
- Best segment Mental Health revenue $36.8M, down $1.0M; volume up 4% but revenue per test down 6%
- Worst segment Cancer Care Continuum revenue $114.1M, down $13.6M; revenue per test down 15%
- Credit facility interest rate 10.1% at June 30, 2026; management expects resources sufficient for at least 12 months
Risk Factors
- No new legal, regulatory, operational, competitive, market, liquidity, debt, currency, or concentration risks disclosed
- No equity repurchases or Rule 10b5-1 trading-plan activity during quarter ended June 30, 2026
AI summary of the MYGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Vishal Sikri promoted to Executive Vice President–Commercial, effective September 16, 2026
- Chief Commercial Officer Brian Donnelly departing Myriad on September 21, 2026
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Brian Donnelly departed as Chief Commercial Officer effective September 16, 2026
- Donnelly remains a non-executive employee through September 21, 2026 for transition support
Item 7.01: Regulation FD Disclosure
- Executive leadership transition: Donnelly departed; Sikri appointed Executive Vice President, Commercial
- Commercial leadership change may affect sales execution, go-to-market strategy, and near-term operating priorities
Item 2.02: Results of Operations and Financial Condition
- Filing contains only signature certification, not substantive Item 2.02 earnings information
Item EX-99.1: Item EX-99.1
- Q2 revenue $190.7M, down 11% YoY; average revenue per test fell 9%, including an $11.0M prior-period collection estimate reduction
- Prenatal Health revenue declined 16% and volume 9%, offsetting Cancer Care volume growth of 6% and Mental Health volume growth of 4%
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Daniel M. Skovronsky, M.D., Ph.D. resigned from Myriad Genetics’ board effective immediately
- Resignation not related to disagreements, operations, policies, or company practices
AI summaries of MYGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MYGN
Don't miss the next MYGN filing
- Alerts as it files. A push when MYGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MYGN, by share count.
- Ask anything. An AI agent that reads every MYGN filing and answers with sources.
MYGN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Wheeler Benjamin Richard | F | Sep 21, 2026 | 2,555 | $4.01 |
| Sikri Vishal | A | Sep 16, 2026 | 257,731 | - |
| Fox Jennifer Lynne | F | Sep 3, 2026 | 4,398 | $3.23 |
| Wheeler Benjamin Richard | F | Aug 16, 2026 | 8,761 | $3.03 |
| Donnelly Brian J | A | Jun 11, 2026 | 5,000 | $3.94 |
| Raha Samraat S. | A | Jun 11, 2026 | 3,542 | $3.94 |
| Kumar Rashmi | Sell | Jun 8, 2026 | 15,000 | $4.46 |
| Bisaro Paul | A | Jun 4, 2026 | 59,701 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $837.6M | $824.5M |
| Gross Profit | $517.0M | $585.4M | $576.6M |
| Operating Income | - | -$123.5M | -$387.2M |
| Net Income | -$263.3M | -$127.3M | -$365.9M |
| Gross Margin | - | 69.9% | 69.9% |
| Op. Margin | - | -14.7% | -47.0% |
| Net Margin | - | -15.2% | -44.4% |
| Balance Sheet | |||
| Total Assets | $1.1B | $1.0B | $706.6M |
| Equity | - | $701.1M | $368.0M |
| ROE | - | -18.2% | -99.4% |
| Per Share | |||
| EPS | - | $-1.41 | $-3.95 |
| Cash Flow | |||
| Operating CF | -$110.9M | -$8.7M | $1.8M |
Source: XBRL data in MYRIAD GENETICS INC (MYGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MYGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $290.0M |
| Q1 2026 | 28 | $205.7M |
| Q4 2025 | 27 | $349.4M |
| Q3 2025 | 28 | $387.4M |
| Q2 2025 | 29 | $295.8M |
| Q1 2025 | 25 | $314.8M |
| Q4 2024 | 20 | $414.2M |
| Q3 2024 | 18 | $476.6M |
- BlackRock+2.00M (+23%)
- Citadel Advisors LLC+1.08M (+239%)
- AQR Capital Management+854.4K (+45%)
- State Street Corp+561.0K (+13%)
- Vanguard Portfolio Management LLC+497.4K (+19%)
- Morgan Stanley−687.6K (-22%)
- Goldman Sachs Group−309.2K (-13%)
- JPMorgan Chase & Co−206.6K (-78%)
- Northern Trust−71.8K (-7%)
- Millennium Management−48.4K (-1%)
- Renaissance Technologies LLC−454.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 202 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MYGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 8-K | Sep 16, 2026 | - | Analysis | - |
| 4 | Sep 8, 2026 | - | - | - |
| SC 13G | Sep 4, 2026 | - | - | |
| 4 | Aug 17, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| SC 13G | Aug 7, 2026 | - | - | |
| 10-Q | Jul 31, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | May 14, 2026 | - | - |
Related Health Care companies
- TKNO · Alpha Teknova, Inc.In Vitro & In Vivo Diagnostic Substances
- CLDX · Celldex Therapeutics, Inc.In Vitro & In Vivo Diagnostic Substances
- IDXX · Idexx LaboratoriesIn Vitro & In Vivo Diagnostic Substances
- NTLA · Intellia Therapeutics, Inc.In Vitro & In Vivo Diagnostic Substances
- LNTH · Lantheus Holdings, Inc.In Vitro & In Vivo Diagnostic Substances
- NEOG · NEOGEN CORPIn Vitro & In Vivo Diagnostic Substances
- QDEL · QuidelOrtho CorpIn Vitro & In Vivo Diagnostic Substances
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
MYGN SEC filings: frequently asked questions
Which institutions hold MYGN stock?
As of June 30, 2026, the largest MYRIAD GENETICS INC (MYGN) holders among the 13F filers tracked by SignalX were BlackRock ($62.2 million), Millennium Management ($37.8 million), State Street Corp ($28.5 million), D.E. Shaw & Co ($26.2 million), Vanguard Capital Management LLC ($23.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MYGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), MYRIAD GENETICS INC (MYGN) reported revenue of $824.5 million (down 1.6% from FY2024) and a net loss of $365.9 million. Diluted EPS was -$3.95. The figures come from the XBRL data in the 10-K.
What did MYGN report in its latest 8-K?
MYRIAD GENETICS INC (MYGN) filed an 8-K on September 16, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 7.01 (Regulation FD Disclosure). Vishal Sikri promoted to Executive Vice President–Commercial, effective September 16, 2026.
What are the latest MYGN SEC filings?
MYRIAD GENETICS INC (MYGN) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on July 31, 2026, an 8-K current report on September 16, 2026 and a Form 4 insider filing on September 22, 2026.
What is MYGN's SEC CIK number?
MYRIAD GENETICS INC (MYGN)'s SEC Central Index Key (CIK) is 899923. EDGAR lists every MYGN filing under that number.
Ask anything about MYGN
The research agent reads MYGN's filings, financials, insider trades and 13F holders, then answers with sources.